# replimune (blogs) — RSS Amplifier Recent posts from the 1 feeds in the RSS Amplifier directory that cover replimune. Page: Feed: --- ## [Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more](https://www.biospace.com/fda/amylyxs-redemption-story-summits-survival-woes-definiums-anxiety-win-more) _2026-08-19 · Jef Akst · Podcasts_ Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide. ## [Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight](https://www.biospace.com/fda/replimune-finally-wins-approval-q2-earnings-wrap-up-psychedelics-stay-in-spotlight) _2026-08-12 · Jef Akst · Podcasts_ After two rejections, Replimune has made it across the regulatory finish line with its advanced melanoma therapy. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again. ## [Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms](https://www.biospace.com/fda/rumors-of-biggest-pharma-merger-ever-drop-amid-q2-earnings-contentious-fda-adcomms) _2026-08-05 · Jef Akst · Podcasts_ The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and… ## [Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more](https://www.biospace.com/fda/capricor-and-replimune-prep-for-fda-adcomms-q2-earnings-roll-on-sareptas-new-leader-more) _2026-07-29 · Heather McKenzie · Podcasts_ The FDA published briefing documents ahead of advisory committee meetings for therapies from Capricor Therapeutics and Replimune indicate an uphill battle for the biotechs; GSK and AstraZeneca outline ambitious plans in second quarter presentations; Sarepta taps Michael Severino as its new CEO; and Amgen launches its official defense of Tavneos. ## [Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2](https://www.biospace.com/drug-development/q2-earnings-underway-fdas-crl-kerfuffle-ipos-full-speed-ahead-in-h2) _2026-07-22 · Jef Akst · Podcasts_ Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.